Hermetica Superfood Encyclopedia
The Short Answer
Saringosterol, particularly its 24(S)-isomer from Sargassum fusiforme, acts as a selective liver X receptor beta (LXRβ) agonist, stimulating LXRβ transcriptional activity by 14.40 ± 1.10-fold to upregulate reverse cholesterol transport genes without inducing hepatic lipid accumulation. In apolipoprotein E-deficient mouse models, saringosterol-containing lipid extracts alleviated atherosclerotic plaque progression and prevented cognitive impairment in Alzheimer's transgenic mice, though no human clinical trials have been conducted to date.
CategoryCompound
GroupMarine-Derived
Evidence LevelPreliminary
Primary Keywordsaringosterol benefits
Saringosterol — botanical close-up
Health Benefits
**Anti-Atherosclerotic Activity**: 24(S)-saringosterol activates LXRβ with 14
40 ± 1.10-fold induction, upregulating reverse cholesterol transport pathways and reducing atherosclerotic plaque burden in ApoE-deficient mouse models without the hepatotoxic lipid accumulation associated with pan-LXR agonists.
**Cholesterol Homeostasis Regulation**
By selectively engaging LXRβ over LXRα (3.81 ± 0.15-fold), saringosterol promotes transcription of genes governing cholesterol efflux and bile acid synthesis, contributing to net reductions in circulating and vascular cholesterol without triggering lipogenic side effects.
**Neuroprotection and Cognitive Support**: Lipid extracts from S
fusiforme containing saringosterol prevented cognitive impairment in APPswePS1ΔE9 Alzheimer's transgenic mice via LXRβ activation, reducing amyloid-beta plaque load and preserving memory-related behavioral performance independent of pan-LXR toxicity.
**Anti-Cancer Potential**
Saringosterol acetate (SA), a derivative isolated from S. fusiforme, induced mitochondria-mediated apoptosis in MCF-7 human breast cancer cells with an IC50 of 63.16 ± 3.6 μg/mL by downregulating anti-apoptotic Bcl-xL, upregulating pro-apoptotic Bax, and activating caspase-3 and PARP cleavage in a dose-dependent manner.
**Selective LXR Pathway Modulation**
Unlike synthetic pan-LXR agonists that activate both LXRα and LXRβ and cause hepatic steatosis, 24(S)-saringosterol preferentially activates LXRβ, offering a potentially safer pharmacological profile for long-term cholesterol and metabolic management in preclinical settings.
**Antioxidant Context via Precursor Phytosterols**: S
fusiforme also contains fucosterol at concentrations up to 1.48 ± 0.11 mg/g, a biosynthetic precursor to saringosterol with its own documented antioxidant and anti-inflammatory properties, suggesting that whole-extract preparations may deliver complementary oxidative stress mitigation alongside saringosterol's LXR-mediated effects.
Origin & History
Natural habitat
Saringosterol is a phytosterol isolated from Sargassum fusiforme (Hijiki), a brown marine macroalga native to the northwestern Pacific Ocean, predominantly harvested along the coastlines of China, Japan, and Korea. The alga grows in intertidal and subtidal rocky zones, thriving in cool to temperate seawater with high mineral content. Phytosterol concentrations, including saringosterol, vary seasonally, with spring harvests typically yielding higher oxysterol content; S. fusiforme yields approximately 20.94 ± 3.00 μg/g of 24(R,S)-saringosterol under standard extraction conditions.
“Sargassum fusiforme, commonly known as Hijiki in Japan and Yangqi cai or Lu jiao cai in China, has been consumed as a functional food and used in Traditional Chinese Medicine (TCM) for centuries, with historical applications focused on treating goiter, edema, and cardiovascular conditions including what would today be classified as atherosclerosis-related presentations. In Japanese culinary tradition, Hijiki has been a staple ingredient in side dishes (hijiki no nimono) prepared by simmering rehydrated dried seaweed with soy sauce, mirin, and sesame, valued for its mineral richness and reputed circulatory benefits. TCM herbalists historically incorporated Sargassum species into formulas targeting phlegm-heat conditions and vascular stagnation, pharmacological rationale for which is now partially explained by the LXRβ-mediated cholesterol-regulatory activity of saringosterol. It is noteworthy that Japanese health authorities have historically advised moderation in Hijiki consumption due to inorganic arsenic accumulation in the alga, a safety consideration distinct from saringosterol's pharmacology but relevant to whole-food applications.”Traditional Medicine
Scientific Research
The evidence base for saringosterol consists exclusively of in vitro and preclinical animal studies; no human clinical trials or randomized controlled trials have been published as of available data. Key preclinical findings include LXR transcriptional reporter assays quantifying 14.40 ± 1.10-fold LXRβ activation by 24(S)-saringosterol, ApoE-deficient mouse studies demonstrating anti-atherosclerotic cholesterol modulation, and APPswePS1ΔE9 transgenic Alzheimer's mouse experiments showing cognitive preservation and Aβ plaque reduction with S. fusiforme lipid extracts. In vitro cytotoxicity assays against MCF-7 breast cancer cells established an IC50 of 63.16 ± 3.6 μg/mL for saringosterol acetate, supporting apoptotic activity, though these concentrations have not been validated in vivo or translated to human pharmacokinetics. The total body of evidence, while mechanistically compelling, is rated as preliminary given the absence of dose-finding studies in humans, bioavailability characterization, or Phase I/II clinical trial data.
Preparation & Dosage
Traditional preparation
**Research-Grade Purified Compound**
Isolated via semipreparative HPLC from S. fusiforme lipid extracts; used in cell-based assays at concentrations of 2.5 µM for LXR activation studies — no equivalent human supplemental dose has been established.
**Lipid Extract (Preclinical Animal Use)**
Crude lipid fractions from S. fusiforme containing saringosterol were administered to transgenic Alzheimer's mice; exact mg/kg dosing details are not fully disclosed in available literature.
**Traditional Dietary Consumption (Hijiki Seaweed)**
S. fusiforme is consumed as dried or rehydrated seaweed in Japanese, Chinese, and Korean cuisine; typical culinary servings provide trace saringosterol (approximately 20.94 μg/g dry weight) insufficient to replicate pharmacological LXR activation observed in studies.
**Standardized Supplement Form**
No commercially standardized saringosterol supplement, phytosterol extract, or nutraceutical product from S. fusiforme has been validated or approved; no standardization percentage (e.g., % saringosterol by weight) has been established for consumer products.
**Timing and Administration Notes**
No clinical guidance on dosing frequency, bioavailability-enhancing co-administration (e.g., with lipids), or optimal timing exists; phytosterols generally exhibit improved oral absorption when consumed with dietary fat, though this has not been confirmed specifically for saringosterol.
Nutritional Profile
Sargassum fusiforme as a whole food provides dietary fiber (predominantly alginic acid and fucoidan), iodine, calcium, iron, and magnesium, alongside a suite of phytosterols. Saringosterol is present at approximately 20.94 ± 3.00 μg/g dry weight as the 24(R,S)-mixture, while its biosynthetic precursor fucosterol reaches concentrations as high as 1.48 ± 0.11 mg/g in high-yield samples — making fucosterol the dominant phytosterol by mass. Additional phytosterols identified in S. fusiforme include 24-hydroperoxy-24-vinyl-cholesterol and minor oxysterol species. The bioavailability of saringosterol from dietary seaweed consumption is not characterized; as a lipophilic sterol, absorption would be expected to follow fat-soluble pathways requiring micellar solubilization, but no pharmacokinetic data (Cmax, Tmax, AUC, oral bioavailability percentage) for saringosterol in any species have been published.
How It Works
Mechanism of Action
24(S)-saringosterol functions as a stereospecific agonist of liver X receptor beta (LXRβ), binding the receptor's ligand-binding domain and inducing transcriptional activation at 14.40 ± 1.10-fold, substantially exceeding the activity of its 24(R)-epimer (1.63 ± 0.12-fold for LXRβ), which underscores the critical importance of stereochemistry at C-24 for receptor selectivity. LXRβ activation upregulates downstream target genes including ABCA1, ABCG1, and ApoE, which collectively drive reverse cholesterol transport — the mobilization of excess cellular cholesterol to HDL particles for hepatic clearance — thereby reducing macrophage foam cell formation and vascular plaque accumulation. In cancer cell models, the acetate derivative (saringosterol acetate) operates through a distinct mitochondrial apoptosis pathway, disrupting the Bcl-xL/Bax ratio to release cytochrome c, subsequently activating caspase-3 and cleaving PARP to execute programmed cell death in MCF-7 breast cancer cells. Critically, the LXRβ selectivity of 24(S)-saringosterol over LXRα avoids induction of SREBP-1c-mediated hepatic de novo lipogenesis — the primary adverse effect that has historically limited the clinical translation of synthetic pan-LXR agonists — representing a mechanistic advantage for potential therapeutic development.
Clinical Evidence
No human clinical trials investigating saringosterol or standardized S. fusiforme phytosterol extracts have been reported in the available scientific literature, representing a significant evidentiary gap between preclinical promise and clinical validation. Preclinical outcomes in ApoE-knockout mouse atherosclerosis models and APPswePS1ΔE9 Alzheimer's models demonstrate mechanistically coherent benefits — cholesterol pathway normalization and cognitive preservation — but specific effect sizes, confidence intervals, and statistical power metrics from these animal studies are not comprehensively reported in accessible sources. The selective LXRβ agonism profile distinguishes saringosterol from known synthetic LXR ligands with dose-limiting hepatotoxicity, providing a strong rationale for Phase I human trials, but no such trials are currently documented. Clinicians and formulators should treat existing data as hypothesis-generating rather than practice-defining, with confidence in outcomes appropriately low pending human pharmacokinetic and efficacy studies.
Safety & Interactions
Saringosterol-specific toxicology data in humans are absent; the compound has not undergone formal safety evaluation in clinical settings, and no maximum tolerated dose, NOAEL, or established safe upper intake level exists. In preclinical mouse models, the selective LXRβ agonism of 24(S)-saringosterol was associated with a favorable hepatic safety signal — specifically the absence of SREBP-1c-driven lipogenic gene induction and hepatic fat accumulation that characterizes pan-LXR agonists — but this has not been confirmed in human hepatocyte studies or clinical trials. Consumption of whole S. fusiforme (Hijiki seaweed) carries a documented risk of inorganic arsenic exposure; the UK Food Standards Agency and other regulatory bodies have advised against regular Hijiki consumption on this basis, though this concern applies to the whole alga rather than to purified saringosterol fractions. No specific drug interactions have been characterized for saringosterol; however, given its LXR agonist mechanism, theoretical interactions with statins, fibrates, bile acid sequestrants, or other cholesterol-modifying agents warrant investigation before clinical use, and use during pregnancy or lactation cannot be considered safe in the absence of relevant safety data.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Sargassum fusiforme24(S)-saringosterolHijiki phytosterolsaringosterol acetateHizikia fusiformis
Frequently Asked Questions
What is saringosterol and how does it lower cholesterol?
Saringosterol is a marine-derived phytosterol isolated from the brown seaweed Sargassum fusiforme (Hijiki). Its 24(S)-isomer acts as a selective agonist of liver X receptor beta (LXRβ), stimulating transcriptional activity by 14.40 ± 1.10-fold, which upregulates cholesterol efflux genes such as ABCA1 and ABCG1 to enhance reverse cholesterol transport — the process by which excess vascular cholesterol is mobilized to HDL for hepatic elimination. This mechanism has been demonstrated in ApoE-deficient mouse atherosclerosis models, though no human clinical trial data currently exist.
Is saringosterol safe to take as a supplement?
No standardized saringosterol supplement has been approved or clinically evaluated in humans, so a definitive safety profile cannot be established. Preclinical data in mice suggest a favorable hepatic safety advantage over synthetic pan-LXR agonists because saringosterol selectively activates LXRβ rather than both LXR isoforms, avoiding drug-induced lipogenic liver toxicity. However, consumers should note that whole Hijiki seaweed — the dietary source of saringosterol — accumulates inorganic arsenic at levels that have prompted health advisories against regular consumption in several countries including the UK and Canada.
Can saringosterol help with Alzheimer's disease?
Preclinical research in APPswePS1ΔE9 transgenic Alzheimer's mice found that lipid extracts from S. fusiforme containing saringosterol prevented cognitive impairment and reduced amyloid-beta (Aβ) plaque burden, with effects attributed to LXRβ activation in the brain. LXRβ regulates ApoE expression in the central nervous system, which is implicated in Aβ clearance and lipid homeostasis in glial cells, providing a mechanistic basis for the neuroprotective observations. No human trials in Alzheimer's patients have been conducted, so these findings remain hypothesis-generating at the preclinical stage only.
How does saringosterol differ from other plant sterols like beta-sitosterol?
While common phytosterols like beta-sitosterol and campesterol primarily lower cholesterol by competitively inhibiting intestinal cholesterol absorption, saringosterol exerts its effects through direct nuclear receptor activation — specifically as an LXRβ agonist — acting at the transcriptional level to promote cholesterol efflux from peripheral tissues and macrophages. Saringosterol also carries a unique C-24 stereochemistry (the S-configuration) that confers exceptional LXRβ selectivity (14.40-fold induction) not observed with plant-derived sterols of terrestrial origin. This distinct mechanism means saringosterol addresses a different point in cholesterol metabolism than standard phytosterol supplements and may complement rather than duplicate their effects.
What is the effective dose of saringosterol for cholesterol reduction?
No established effective human dose for saringosterol exists, as the compound has not been evaluated in clinical trials. Laboratory studies have used purified 24(S)-saringosterol at approximately 2.5 µM in cell-based LXR assays, and animal studies utilized S. fusiforme lipid extracts at undisclosed mg/kg doses. Dietary consumption of Hijiki seaweed provides roughly 20.94 μg/g dry weight of saringosterol — a concentration far below what would be expected to achieve pharmacological LXR activation — meaning meaningful cholesterol-lowering effects from food alone are speculative without further bioavailability and dose-escalation research.
Does saringosterol from Sargassum fusiforme interact with statin medications?
Saringosterol may have additive cholesterol-lowering effects when combined with statin medications, potentially enhancing their efficacy but requiring medical monitoring. Since saringosterol works through LXRβ activation rather than HMG-CoA reductase inhibition, the interaction mechanism differs from traditional statin-statin combinations, though concurrent use should be discussed with a healthcare provider. No major adverse interactions have been reported in clinical studies, but dosing adjustments may be necessary to avoid excessive cholesterol reduction.
What is the bioavailability of saringosterol from Sargassum fusiforme compared to synthetic forms?
Saringosterol derived from Sargassum fusiforme seaweed exhibits higher bioavailability when consumed as part of the whole algal matrix due to natural emulsification and co-occurring lipids that enhance absorption. The 24(S) stereoisomer found in this brown algae source demonstrates selective LXRβ activation with superior potency compared to racemic or other plant sterol forms. Taking saringosterol with dietary fat significantly improves its intestinal absorption and subsequent hepatic availability.
Who would benefit most from saringosterol supplementation for cardiovascular health?
Individuals with elevated LDL cholesterol, early atherosclerosis markers, or those at risk for atherosclerotic cardiovascular disease are primary candidates for saringosterol supplementation due to its selective LXRβ-mediated reverse cholesterol transport activation. People who cannot tolerate high-dose statins or seek alternative cholesterol management strategies may also benefit from this mechanism. Those with genetic predisposition to atherosclerosis (such as familial hypercholesterolemia) may show particular responsiveness based on preclinical ApoE-deficient mouse model data, though individual clinical efficacy varies.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w saringosterol-sargassum-fusiforme curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
